Description of Eosinophilic Pneumonia in BJI/PJI Treated by Daptomycin

Status Recruiting

Clinical Trial Summary

Daptomycin is an antibiotic from the family of cyclic lipopeptides, bactericide, concentration-dependent. Its spectrum concerns Gram-positive bacteria. Since the authorization of daptomycin in 2006, cases of eosinophilic pneumonia and pulmonary eosinophilia associated with its use have been reported in Europe and worldwide. The purpose of this study is to describe the mechanism of occurrence of this AE with dapto; Prolonged exposure and accumulation at the alveolar level could potentially have a role. Better understanding the mechanisms of appearance of this AE would provide predictive elements making it possible to limit the occurrence of this AE in the future

Clinical Trial Description

Daptomycin is an antibiotic from the family of cyclic lipopeptides, bactericide, concentration-dependent. Its spectrum concerns Gram-positive bacteria. The Infectious Diseases Society of America recommends the use of daptomycin 6 mg / kg / day in the second-line treatment of IOA on staphylococcal but also enterococcal prostheses, as an alternative to vancomycin and linezolid. In case of renal failure, daptomycin is often considered as a good therapeutic alternative to glycopeptides. Since the authorization of daptomycin in 2006, cases of eosinophilic pneumonia and pulmonary eosinophilia associated with its use have been reported in Europe and worldwide. Although a large proportion of cases have been reported in patients receiving daptomycin in unapproved indications, the use of daptomycin in authorized indications has also been associated with this risk. The dosage of daptomycin makes it possible to evaluate its effectiveness and prevent the occurrence of a overdose, provider of side effects. The purpose of this study is to describe the mechanism of occurrence of this AE with dapto; Prolonged exposure and accumulation at the alveolar level could potentially have a role. Better understanding the mechanisms of appearance of this AE would provide predictive elements making it possible to limit the occurrence of this AE in the future ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04414137
Study type	Observational
Source	Hospices Civils de Lyon
Contact	Eugénie Mabrut, CRA
Phone	04 26 73 29 38
Email	eugenie.mabrut@chu-lyon.fr
Status	Recruiting
Phase
Start date	February 19, 2019
Completion date	September 1, 2021

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT05421312` - Periarticular Penetration of Cefazolin and Clindamycin in Second Stage Revision Arthroplasty of the Hip	Phase 4
Active, not recruiting	`NCT04563325` - Oral-only Antibiotics for Bone and Joint Infections in Children	Phase 4
Completed	`NCT03627000` - Microbiological Epidemiology in Patients Experiencing Microbiological or Clinical Failure Following Reimplantation After a 2-stage Exchange Strategy for Hip or Knee Prosthetic Joint Infection
Completed	`NCT03311113` - Adherence to Oral Antibiotics In Patients With Osteoarticular Infections
Recruiting	`NCT05753215` - Controlled Trial of Omadacycline Randomized Treatment Given for Bone and Joint Infection	Phase 2
Completed	`NCT03209921` - Pharmacokinetic Variability of Daptomycin During Prolonged Therapy for Bone and Joint Infections	N/A
Completed	`NCT04418882` - Septic Management and Outcome of Open Fracture
Completed	`NCT05248490` - Impact of Pharmaceutical Interviews Regarding the Management of Adverse Effects Related to the Antibiotic Therapy Used to Treat Osteoarticular Infections During Return Home	N/A
Completed	`NCT03624855` - Implant-Associated P. Aeruginosa Bone And Joint Infections : Experience In A Regional Reference Center In France
Recruiting	`NCT04496024` - Ofloxacin Concentration-toxicity Relationship in the Elderly	N/A
Recruiting	`NCT04933344` - Pharmacokinetics and Toxicodynamics of Daptomycin in Bone and Joint Infections
Recruiting	`NCT04538053` - BonE and Joint Infections - Simplifying Treatment in Children Trial	Phase 4
Completed	`NCT04373278` - Infection After Free Fibula Flap Reconstruction of the Mandible: a Retrospective Cohort Study
Completed	`NCT03209934` - Daptomycin > 6 mg/kg/Day as Salvage Therapy in Patients With Complex Bone and Joint Infection: Cohort Study in a Regionalreference Center	N/A
Recruiting	`NCT02817711` - Lyon BJI Cohort Study	N/A
Recruiting	`NCT03611634` - Consitution Of A Biological Collection From Samples From The Gut Microbiote In Patients Having A Bone Or Joint Infection Treated By A Suppressive Subcutaneous Antibiotherapy With Betalactamine
Completed	`NCT03177369` - Teicoplanin-based Antimicrobial Therapy in Staphylococcus Aureus Bone and Joint Infection: Tolerance, Efficacy and Experience With Subcutaneous Administration	N/A
Recruiting	`NCT04722926` - Lyon PJI Retrospective Cohort Study
Completed	`NCT03852784` - Osteoarticular Infections With Pneumococcal
Recruiting	`NCT03796104` - Prognostic Impact of Delta-haemolysin Production Deficiency in Staphylococcus Aureus on the Prognosis of Infected Implant Treated by DAIR